epivax computational tool (EpiVax Inc)
90
Structured Review
EpiVax Inc
epivax computational tool
Epivax Computational Tool, supplied by EpiVax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/computation+tool/epivax+computational+tool/pmc07443330-45-10-10
Average 90 stars, based on 1 article reviews
Epivax Computational Tool, supplied by EpiVax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/computation+tool/epivax+computational+tool/pmc07443330-45-10-10
Average 90 stars, based on 1 article reviews
epivax computational tool - by Bioz Stars,
2026-11
90/100 stars
Images
Related Articles
Sequencing:Article Title: Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development Article Snippet: Generex/EpiVax , Generex Biotechnology Corporation will use EpiVax expertise and computational tools to predict epitopes that can be used to generate peptide vaccines against SARS-CoV-2 using the patented NuGenerex Immuno-Oncology (NGIO – Formerly Antigen Express) Ii-Key technology , Pre-Clinical , (“Generex. Generex Signs Contract with EpiVax to Develop Ii-Key Peptide Vaccines to Address the Coronavirus Pandemic. March 04, 202. https://epivax.com/news/press-release-generex-signs-contract-with-epivax-to-develop-ii-key-peptide-vaccines-to-address-the-coronavirus-pandemic . Accessed May 21, 2020.,” n.d.). .. EpiVax/Univ. of Georgia , Sequence will be predicted based on Bioprocessing:Article Title: Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development Article Snippet: Generex/EpiVax , Generex Biotechnology Corporation will use EpiVax expertise and computational tools to predict epitopes that can be used to generate peptide vaccines against SARS-CoV-2 using the patented NuGenerex Immuno-Oncology (NGIO – Formerly Antigen Express) Ii-Key technology , Pre-Clinical , (“Generex. Generex Signs Contract with EpiVax to Develop Ii-Key Peptide Vaccines to Address the Coronavirus Pandemic. March 04, 202. https://epivax.com/news/press-release-generex-signs-contract-with-epivax-to-develop-ii-key-peptide-vaccines-to-address-the-coronavirus-pandemic . Accessed May 21, 2020.,” n.d.). .. EpiVax/Univ. of Georgia , Sequence will be predicted based on Vaccines:Article Title: Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development Article Snippet: Generex/EpiVax , Generex Biotechnology Corporation will use EpiVax expertise and computational tools to predict epitopes that can be used to generate peptide vaccines against SARS-CoV-2 using the patented NuGenerex Immuno-Oncology (NGIO – Formerly Antigen Express) Ii-Key technology , Pre-Clinical , (“Generex. Generex Signs Contract with EpiVax to Develop Ii-Key Peptide Vaccines to Address the Coronavirus Pandemic. March 04, 202. https://epivax.com/news/press-release-generex-signs-contract-with-epivax-to-develop-ii-key-peptide-vaccines-to-address-the-coronavirus-pandemic . Accessed May 21, 2020.,” n.d.). .. EpiVax/Univ. of Georgia , Sequence will be predicted based on |